Should I buy or sell Intercept Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares. View ICPT analyst ratings or view top-rated stocks .

What is Intercept Pharmaceuticals' stock price target for 2024?

6 Wall Street research analysts have issued 12-month price targets for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $31.00. On average, they expect the company's stock price to reach $19.86 in the next year. This suggests a possible upside of 4.5% from the stock's current price. View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts .

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.42. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analysts' expectations of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 77.48% and a negative net margin of 19.39%. The company's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.68) EPS.

What ETF holds Intercept Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com . Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT) , Gilead Sciences (GILD) , Tesla (TSLA) , NVIDIA (NVDA) , Netflix (NFLX) , Alibaba Group (BABA) , Micron Technology (MU) , Ionis Pharmaceuticals (IONS) , Regeneron Pharmaceuticals (REGN) and Biogen (biib) .

NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ICPT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $19.00
▼
$19.00
50-Day Range: $18.20
▼
$19.00
52-Week Range: $8.82
▼
$21.86

Volume: N/A
Average Volume: 1.36 million shs
Market Capitalization: $794.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.86

Stock Analysis Analyst Forecasts Earnings Headlines Ownership Social Media Sustainability

Get Intercept Pharmaceuticals alerts:

Intercept Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 4.5% Upside
$19.86 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.13
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.04) to $1.93 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.33 out of 5 stars

Medical Sector

899th out of 930 stocks

Biotechnology Industry

24th out of 28 stocks

1.0

Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Intercept Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ICPT.

0.0

Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Intercept Pharmaceuticals is -2.13.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.
Percentage Held by Institutions
83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intercept Pharmaceuticals has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ICPT Stock News Headlines

March 21, 2024 | msn.com

89bio gains 47% on topline data for NASH candidate

February 29, 2024 | globenewswire.com

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 13, 2023 | finance.yahoo.com

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023

November 10, 2023 | finance.yahoo.com

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023

November 8, 2023 | finance.yahoo.com

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

November 2, 2023 | msn.com

Intercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38

October 31, 2023 | finance.yahoo.com

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 27, 2023 | finance.yahoo.com

Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now

October 11, 2023 | finance.yahoo.com

Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago

October 5, 2023 | msn.com

Intercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17

September 28, 2023 | msn.com

Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say

September 28, 2023 | msn.com

Canaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)

September 27, 2023 | markets.businessinsider.com

Intercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value Assessment

September 27, 2023 | proactiveinvestors.com

Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal

September 26, 2023 | msn.com

Canaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"

September 26, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma

September 26, 2023 | seekingalpha.com

Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties

September 26, 2023 | investorplace.com

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

September 26, 2023 | marketwatch.com

Intercept Pharma Shares Surge Toward Alfasigma Acquisition Price

September 26, 2023 | msn.com

Intercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premium

September 26, 2023 | reuters.com

Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln

September 26, 2023 | markets.businessinsider.com

Alfasigma To Acquire Intercept Pharma Fo $19 Per Share In Cash

September 26, 2023 | markets.businessinsider.com

Why Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?

September 26, 2023 | finance.yahoo.com

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

September 26, 2023 | finance.yahoo.com

UPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mln

See More Headlines

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/02/2023
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ICPT
CUSIP: 45845P10
CIK: 1270073
Web: www.interceptpharma.com
Phone: (646) 747-1000
Fax: 646-747-1001
Employees: 341
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.86
High Stock Price Target: $31.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +4.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $221.82 million
Net Margins: -19.39%
Pretax Margin: -18.09%
Return on Equity: -77.48%
Return on Assets: -11.99%

Debt

Debt-to-Equity Ratio: 3.12
Current Ratio: 4.22
Quick Ratio: 2.52

Sales & Book Value

Annual Sales: $285.71 million
Price / Sales: 2.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.72 per share
Price / Book: 11.05

Miscellaneous

Outstanding Shares: 41,830,000
Free Float: 39,192,000
Market Cap: $794.77 million
Optionable: Optionable
Beta: 0.88

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Jerome B. Durso (Age 55)
President, CEO & Director
Comp: $1.37M
Mr. Andrew Saik (Age 54)
Chief Financial Officer
Comp: $888.6k
Mr. Jared M. Freedberg J.D. (Age 55)
General Counsel
Comp: $812.55k
Ms. Linda M. Richardson (Age 59)
Executive VP & Chief Commercial Officer
Comp: $837.73k
Dr. M. Michelle Berrey M.D. (Age 56)
M.P.H., President of Research & Development and Chief Medical Officer
Comp: $1.12M
Mr. Rocco Venezia (Age 47)
Chief Accounting Officer & Treasurer
Comp: $660.62k
Mr. Nareg Sagherian
Executive Director of Global Investor Relations
Mr. David Ford (Age 53)
Chief Human Resources Officer
Comp: $434.9k
Dr. Mark Pruzanski M.D. (Age 55)
Founder, Advisor & Director
Comp: $1.3M
Paul Nitschmann
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ICPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings or view top-rated stocks.
What is Intercept Pharmaceuticals' stock price target for 2024?: 6 Wall Street research analysts have issued 12-month price targets for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $31.00. On average, they expect the company's stock price to reach $19.86 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.
How were Intercept Pharmaceuticals' earnings last quarter?: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.42. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analysts' expectations of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 77.48% and a negative net margin of 19.39%. The company's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.68) EPS.
What ETF holds Intercept Pharmaceuticals' stock?: Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?: 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Intercept Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

This page (NASDAQ:ICPT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Intercept Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

ICPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ICPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™